{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:40:04Z","timestamp":1784864404513,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["PUTJD914"],"award-info":[{"award-number":["PUTJD914"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["IUT 20-42"],"award-info":[{"award-number":["IUT 20-42"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["IUT 20-42"],"award-info":[{"award-number":["IUT 20-42"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["IUT 20-42"],"award-info":[{"award-number":["IUT 20-42"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["Project 2014-2020.4.01.15-0012"],"award-info":[{"award-number":["Project 2014-2020.4.01.15-0012"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["Project 2014-2020.4.01.15-0012"],"award-info":[{"award-number":["Project 2014-2020.4.01.15-0012"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["Project 2014-2020.4.01.15-0012"],"award-info":[{"award-number":["Project 2014-2020.4.01.15-0012"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hypoxia is a contributing factor for the morbidity and mortality in patients with obstructive sleep apnea (OSA). We aimed at identifying the percentage of sleep time with oxyhemoglobin desaturation below 90% (Tc90%) breakpoint from which the most significant changes occur in systemic metabolome of patients with OSA. In a prospective observational study on patients with polysomnography\u2013confirmed symptomatic OSA, profiles of 186 metabolites including amino acids, biogenic amines, acylcarnitines (AC), lysophosphatidylcholines, phosphatidylcholines (PC) and sphingomyelins (SM) were analyzed with liquid chromatography-mass-spectrometry in peripheral blood, obtained at 3 time points that covered patients\u2019 night sleep. Comparisons of rank-transformed data with general linear model for repeated measures after dichotomizing the study group at different Tc90% levels were applied to define the best cut-off, hypoxic metabolic threshold (HMT), based on Cohen\u2019s f. Fifty-one subjects were recruited with their median Tc90% of 2.1. The mean Cohen\u2019s f over the metabolites was highest (0.165) at a Tc90% of 1.8 representing the HMT. Of the different classes of metabolites, the Cohen\u2019s f value at HMT was highest for SM (0.322). Compared to patients with Tc90% &lt; HMT, concentrations of 2 PC, 1 AC and 7 SM were significantly higher in patients with Tc90% \u2265HMT. The HMT for patients with OSA described in this report for the first time is located at a Tc90% level of 1.8 with SM levels contributing most to the size of this threshold. <\/jats:p>","DOI":"10.1038\/s41598-025-96386-9","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:32:36Z","timestamp":1744399956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum sphingomyelin levels define oxyhemoglobin desaturation-related metabolic threshold in symptomatic obstructive sleep apnea"],"prefix":"10.1038","volume":"15","author":[{"given":"Ott","family":"Kiens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egon","family":"Taalberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketlin","family":"Veev\u00e4li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triin","family":"Laurits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragne","family":"Tamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigar","family":"Ottas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalle","family":"Kilk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursel","family":"Soomets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Altraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"15","key":"96386_CR1","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1056\/NEJMcp1816152","volume":"380","author":"SC Veasey","year":"2019","unstructured":"Veasey, S. C. & Rosen, I. M. Obstructive sleep apnea in adults. N Engl. J. Med. 380 (15), 1442\u20131449 (2019).","journal-title":"N Engl. J. Med."},{"issue":"13","key":"96386_CR2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/eurheartj\/ehn214","volume":"29","author":"IH Stevenson","year":"2008","unstructured":"Stevenson, I. H. et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur. Heart J. 29 (13), 1662\u20131669 (2008).","journal-title":"Eur. Heart J."},{"issue":"8","key":"96386_CR3","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/sleep\/20.8.608","volume":"20","author":"T Young","year":"1997","unstructured":"Young, T., Blustein, J., Finn, L. & Palta, M. Sleep-disordered breathing and motor vehicle accidents in a population-based sample of employed adults. Sleep 20 (8), 608\u2013613 (1997).","journal-title":"Sleep"},{"issue":"3","key":"96386_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1164\/rccm.200912-1869OC","volume":"182","author":"JM Marin","year":"2010","unstructured":"Marin, J. M., Soriano, J. B., Carrizo, S. J., Boldova, A. & Celli, B. R. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am. J. Respir Crit. Care Med. 182 (3), 325\u2013331 (2010).","journal-title":"Am. J. Respir Crit. Care Med."},{"issue":"2","key":"96386_CR5","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung, K. F. et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir J. 43 (2), 343\u2013373 (2014).","journal-title":"Eur. Respir J."},{"issue":"5","key":"96386_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/sleep\/22.5.667","volume":"22","author":"Sleep-related breathing","year":"1999","unstructured":"Sleep-related breathing. Disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American academy of sleep medicine task force. Sleep 22 (5), 667\u2013689 (1999).","journal-title":"Sleep"},{"issue":"4","key":"96386_CR7","doi-asserted-by":"publisher","first-page":"e13066","DOI":"10.1111\/jsr.13066","volume":"29","author":"DA Pevernagie","year":"2020","unstructured":"Pevernagie, D. A. et al. On the rise and fall of the apnea-hypopnea index: A historical review and critical appraisal. J. Sleep. Res. 29 (4), e13066 (2020).","journal-title":"J. Sleep. Res."},{"issue":"5","key":"96386_CR8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.5665\/sleep.5776","volume":"39","author":"DW Hudgel","year":"2016","unstructured":"Hudgel, D. W. Sleep apnea severity Classification - Revisited. Sleep 39 (5), 1165\u20131166 (2016).","journal-title":"Sleep"},{"issue":"21","key":"96386_CR9","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/eurheartj\/ehv624","volume":"37","author":"O Oldenburg","year":"2016","unstructured":"Oldenburg, O. et al. Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients. Eur. Heart J. 37 (21), 1695\u20131703 (2016).","journal-title":"Eur. Heart J."},{"key":"96386_CR10","doi-asserted-by":"publisher","first-page":"808417","DOI":"10.3389\/fmed.2022.808417","volume":"9","author":"P Landete","year":"2022","unstructured":"Landete, P. et al. Increased oxygen desaturation time during sleep is a risk factor for NASH in patients with obstructive sleep apnea: A prospective cohort study. Front. Med. (Lausanne). 9, 808417 (2022).","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"96386_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12974-020-01905-2","volume":"17","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome. J. Neuroinflammation. 17 (1), 229 (2020).","journal-title":"J. Neuroinflammation"},{"issue":"9","key":"96386_CR12","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.5664\/jcsm.7336","volume":"14","author":"H Xu","year":"2018","unstructured":"Xu, H. et al. Pediatric obstructive sleep apnea is associated with changes in the oral Microbiome and urinary metabolomics profile: A pilot study. J. Clin. Sleep. Med. 14 (9), 1559\u20131567 (2018).","journal-title":"J. Clin. Sleep. Med."},{"key":"96386_CR13","doi-asserted-by":"publisher","first-page":"30958","DOI":"10.1038\/srep30958","volume":"6","author":"H Xu","year":"2016","unstructured":"Xu, H. et al. Metabolomics profiling for obstructive sleep apnea and simple snorers. Sci. Rep. 6, 30958 (2016).","journal-title":"Sci. Rep."},{"issue":"1","key":"96386_CR14","doi-asserted-by":"publisher","first-page":"10811","DOI":"10.1038\/s41598-021-88409-y","volume":"11","author":"O Kiens","year":"2021","unstructured":"Kiens, O. et al. The effect of obstructive sleep apnea on peripheral blood amino acid and biogenic amine metabolome at multiple time points overnight. Sci. Rep. 11 (1), 10811 (2021).","journal-title":"Sci. Rep."},{"key":"96386_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jpba.2013.06.032","volume":"87","author":"HG Gika","year":"2014","unstructured":"Gika, H. G., Theodoridis, G. A., Plumb, R. S. & Wilson, I. D. Current practice of liquid chromatography-mass spectrometry in metabolomics and metabonomics. J. Pharm. Biomed. Anal. 87, 12\u201325 (2014).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"1","key":"96386_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/acs.analchem.6b02930","volume":"89","author":"AP Siskos","year":"2017","unstructured":"Siskos, A. P. et al. Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal. Chem. 89 (1), 656\u2013665 (2017).","journal-title":"Anal. Chem."},{"key":"96386_CR17","doi-asserted-by":"crossref","unstructured":"Kiens, O. et al. Apnoea-hypopnoea index of 5 events.h(-1) as a metabolomic threshold in patients with sleep complaints. ERJ Open. Res. ;9(1). (2023).","DOI":"10.1183\/23120541.00325-2022"},{"issue":"7836","key":"96386_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41586-020-2896-2","volume":"588","author":"N Bar","year":"2020","unstructured":"Bar, N. et al. A reference map of potential determinants for the human serum metabolome. Nature 588 (7836), 135\u2013140 (2020).","journal-title":"Nature"},{"key":"96386_CR19","doi-asserted-by":"crossref","unstructured":"Steinhauser, M. L. et al. The Circulating metabolome of human starvation. JCI Insight ;3(16). (2018).","DOI":"10.1172\/jci.insight.121434"},{"issue":"3","key":"96386_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1378\/chest.15-0903","volume":"149","author":"F Chung","year":"2016","unstructured":"Chung, F., Abdullah, H. R., Liao, P. & STOP-Bang Questionnaire A practical approach to screen for obstructive sleep apnea. Chest 149 (3), 631\u2013638 (2016).","journal-title":"Chest"},{"key":"96386_CR21","volume-title":"The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.2. Darien","author":"RB Berry","year":"2015","unstructured":"Berry, R. B. et al. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.2. Darien (American Academy of Sleep Medicine, 2015)."},{"key":"96386_CR22","volume-title":"International Classification of Sleep Disorders","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine. International Classification of Sleep Disorders 3rd edn. (American Academy of Sleep Medicine, 2014).","edition":"3"},{"issue":"7","key":"96386_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00403-017-1760-1","volume":"309","author":"A Ottas","year":"2017","unstructured":"Ottas, A., Fishman, D., Okas, T. L., Kingo, K. & Soomets, U. The metabolic analysis of psoriasis identifies the associated metabolites while providing computational models for the monitoring of the disease. Arch. Dermatol. Res. 309 (7), 519\u2013528 (2017).","journal-title":"Arch. Dermatol. Res."},{"key":"96386_CR24","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen, J. Statistical Power Analysis for the Behavioral Sciences (Lawrence Erlbaum Associates, 1988)."},{"issue":"1","key":"96386_CR25","doi-asserted-by":"publisher","first-page":"14085","DOI":"10.1038\/s41598-020-71008-8","volume":"10","author":"EJ Gonzalez-Ramirez","year":"2020","unstructured":"Gonzalez-Ramirez, E. J., Garcia-Arribas, A. B., Sot, J., Goni, F. M. & Alonso, A. C24:0 and C24:1 sphingolipids in cholesterol-containing, five- and six-component lipid membranes. Sci. Rep. 10 (1), 14085 (2020).","journal-title":"Sci. Rep."},{"key":"96386_CR26","doi-asserted-by":"publisher","first-page":"178910","DOI":"10.1155\/2013\/178910","volume":"2013","author":"R Pralhada Rao","year":"2013","unstructured":"Pralhada Rao, R. et al. Sphingolipid metabolic pathway: an overview of major roles played in human diseases. J. Lipids. 2013, 178910 (2013).","journal-title":"J. Lipids"},{"issue":"6","key":"96386_CR27","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1194\/jlr.M600040-JLR200","volume":"47","author":"J Dong","year":"2006","unstructured":"Dong, J. et al. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. J. Lipid Res. 47 (6), 1307\u20131314 (2006).","journal-title":"J. Lipid Res."},{"issue":"3","key":"96386_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1172\/JCI131838","volume":"130","author":"AM Poss","year":"2020","unstructured":"Poss, A. M. et al. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. J. Clin. Invest. 130 (3), 1363\u20131376 (2020).","journal-title":"J. Clin. Invest."},{"issue":"1","key":"96386_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10654-017-0333-0","volume":"33","author":"A Floegel","year":"2018","unstructured":"Floegel, A. et al. Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted metabolomic approach in two German prospective cohorts. Eur. J. Epidemiol. 33 (1), 55\u201366 (2018).","journal-title":"Eur. J. Epidemiol."},{"issue":"3","key":"96386_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3892\/etm.2013.1455","volume":"7","author":"H Zheng","year":"2014","unstructured":"Zheng, H. et al. Sphingomyelin levels in nondipper and dipper hypertensive patients. Exp. Ther. Med. 7 (3), 599\u2013603 (2014).","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"96386_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41556-022-01027-2","volume":"25","author":"K Griess","year":"2023","unstructured":"Griess, K. et al. Sphingolipid subtypes differentially control proinsulin processing and systemic glucose homeostasis. Nat. Cell. Biol. 25 (1), 20\u201329 (2023).","journal-title":"Nat. Cell. Biol."},{"issue":"8","key":"96386_CR32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.200905-0773OC","volume":"180","author":"PE Peppard","year":"2009","unstructured":"Peppard, P. E., Ward, N. R. & Morrell, M. J. The impact of obesity on oxygen desaturation during sleep-disordered breathing. Am. J. Respir Crit. Care Med. 180 (8), 788\u2013793 (2009).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"96386_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rmed.2017.01.004","volume":"124","author":"SW Littleton","year":"2017","unstructured":"Littleton, S. W. & Tulaimat, A. The effects of obesity on lung volumes and oxygenation. Respir Med. 124, 15\u201320 (2017).","journal-title":"Respir Med."},{"issue":"9","key":"96386_CR34","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/hr.2010.153","volume":"33","author":"J Wolf","year":"2010","unstructured":"Wolf, J., Hering, D. & Narkiewicz, K. Non-dipping pattern of hypertension and obstructive sleep apnea syndrome. Hypertens. Res. 33 (9), 867\u2013871 (2010).","journal-title":"Hypertens. Res."},{"issue":"9 Pt B","key":"96386_CR35","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","volume":"1859","author":"JN van der Veen","year":"2017","unstructured":"van der Veen, J. N. et al. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim. Biophys. Acta Biomembr. 1859 (9 Pt B), 1558\u20131572 (2017).","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"3","key":"96386_CR36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1124\/pharmrev.121.000408","volume":"74","author":"M Dambrova","year":"2022","unstructured":"Dambrova, M. et al. Acylcarnitines: nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials. Pharmacol. Rev. 74 (3), 506\u2013551 (2022).","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"96386_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.advms.2020.12.001","volume":"66","author":"N Kozar","year":"2021","unstructured":"Kozar, N. et al. Identification of novel diagnostic biomarkers in endometrial cancer using targeted metabolomic profiling. Adv. Med. Sci. 66 (1), 46\u201351 (2021).","journal-title":"Adv. Med. Sci."},{"issue":"7","key":"96386_CR38","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3109\/07420528.2012.699122","volume":"29","author":"JE Ang","year":"2012","unstructured":"Ang, J. E. et al. Identification of human plasma metabolites exhibiting time-of-day variation using an untargeted liquid chromatography-mass spectrometry metabolomic approach. Chronobiol Int. 29 (7), 868\u2013881 (2012).","journal-title":"Chronobiol Int."},{"issue":"14","key":"96386_CR39","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jama.2020.3514","volume":"323","author":"DJ Gottlieb","year":"2020","unstructured":"Gottlieb, D. J. & Punjabi, N. M. Diagnosis and management of obstructive sleep apnea: A review. JAMA 323 (14), 1389\u20131400 (2020).","journal-title":"JAMA"},{"issue":"6","key":"96386_CR40","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1006\/cyto.1999.0665","volume":"12","author":"M Haack","year":"2000","unstructured":"Haack, M. et al. Effects of an intravenous catheter on the local production of cytokines and soluble cytokine receptors in healthy men. Cytokine 12 (6), 694\u2013698 (2000).","journal-title":"Cytokine"},{"issue":"1","key":"96386_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.arbres.2022.08.005","volume":"59","author":"MA Martinez-Garcia","year":"2023","unstructured":"Martinez-Garcia, M. A., Sanchez-de-la-Torre, M., White, D. P. & Azarbarzin, A. Hypoxic burden in obstructive sleep apnea: present and future. Arch. Bronconeumol. 59 (1), 36\u201343 (2023).","journal-title":"Arch. Bronconeumol."},{"key":"96386_CR42","doi-asserted-by":"crossref","unstructured":"Malhotra, A. et al. Metrics of sleep apnea severity: beyond the apnea-hypopnea index. Sleep ;44(7). (2021).","DOI":"10.1093\/sleep\/zsab030"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96386-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96386-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96386-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:32:39Z","timestamp":1744399959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96386-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96386"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96386-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"26 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"O. Kiens has received lecture fees from AstraZeneca, Berlin-Chemie Menarini, GlaxoSmithKline, Norameda, Novartis and Sanofi and sponsorships from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Norameda. None of the conflicts of interest has been related to the current study. A. Altraja has received lecture fees from Abbott, AstraZeneca, Bayer, Berlin-Chemie Menarini, Boehringer Ingelheim, Norameda, GlaxoSmithKline, Janssen, KRKA, MSD, Novartis, Orion, Pfizer, Roche, Sanofi, Takeda, Teva and Zentiva, sponsorships from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Norameda, CSL Behring, GlaxoSmithKline, Janssen, KRKA, MSD, Novartis, Roche, Sanofi, Takeda, Teva and AOP Orphan and research support from AstraZeneca, Bayer, Berlin-Chemie Menarini, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Medis, Norameda, Pfizer and Takeda and has been participated in advisory boards of AstraZeneca, Bayer, Berlin-Chemie Menarini, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Janssen, Johnson & Johnson, MSD, Novartis, Roche, Sanofi, Shire Pharmaceuticals and Teva. None of the conflicts of interest has been related to the current study however. V. Ivanova has received lecture fees from AstraZeneca, Berlin-Chemie Menarini and Norameda. K. Veev\u00e4li, T. Laurits, R Tamm, E. Taalberg, A. Ottas and K. Kilk report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was funded by the institutional research grant IUT 20\u201342 and the EU through the European Regional Development Fund (Project 2014-2020.4.01.15-0012) in addition to the Estonian Research Council grant (PUTJD914). The PSG studies done with Nox A1 polysomnograph were funded by ResMed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Support statement"}}],"article-number":"12533"}}